Biomarker · Gene alteration

IDH1 mutation

IDH1 codon 132 mutations detected by PCR or sequencing (or R132H-specific immunohistochemistry in glioma); used as a predictive marker for IDH1 inhibitors in acute myeloid leukemia and cholangiocarcinoma and as a diagnostic marker in glioma.

CI-BIO-00000047IDH1 graph →NCIt C118389

Also calledIDH1-mutated · IDH1 R132 · R132H · R132C

Derived

Associated cancers (13)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Acute Myeloid Leukemia	11	6	3	2	1 / 6 / 1 / 3 / 0
Anaplastic Astrocytoma	2	—	2	—	0 / 2 / 0 / 0 / 0
Cholangiocarcinoma	2	2	—	—	1 / 1 / 0 / 0 / 0
Glioblastoma	2	—	2	—	0 / 2 / 0 / 0 / 0
High-Grade Glioma, NOS

Derived

Drugs with predictive evidence (11)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
IvosidenibSmall Molecule	6	6	—	A	6 / 0	Acute Myeloid Leukemia, Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma
VorasidenibSmall Molecule	2	2	—	A	6 / 0	Glioma

Curated evidence

Predictive evidence items (18)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–18 of 18 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
IDH1 R132C6
BPTES	Acute Myeloid Leukemia

Regulatory

Approvals mentioning the linked drugs (260)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

IDH1 Mutation4
Ivosidenib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	3	accepted	EID7278 I phase 1 trial for patients with IDH1-mutated AML, patients who received ivosidenib (AG-120). The rate of complete remission was 21.6%, the over all response rate was 30.4%. PMID 29860938 · DiNardo et al., 2018 · Open in CIViC	civic
Venetoclax	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID8856 In this case series, 7 elderly patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA (including 1 patient with antecedent myeloproliferative neoplasm) were t… (full text at CIViC) PMID 30725494 · Huemer et al., 2019 · Open in CIViC	civic
Ivosidenib	Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID7447 In a phase1 trial, 73 patients with cholangiocarcinoma harboring IDH1 mutations were treated with mutant IDH1 inhibitor ivosidenib. The response rate was 5%, median progression free survival was 3.8 m… (full text at CIViC) PMID 31300360 · Lowery et al., 2019 · Open in CIViC	civic
Olaparib	Brain GliomaUNRESOLVED	Predictive	D	Supports Sensitivity Response	3	accepted	EID2933 Mutations in isocitrate dehydrogenase 1 and 2, which result in overproduction of 2-hydroxyglutarate (2HG). 2HG is considered to be an oncometabolite, or a metabolite that promotes carcinogenesis, and … (full text at CIViC) PMID 28148839 · Sulkowski et al., 2017 · Open in CIViC	civic

IDH1 R132H2
AGI-5198	OligodendrogliomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID979 In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations. A phase I clinical trial of the AG-120 IDH1 inhibit… (full text at CIViC) PMID 23558169 · Rohle et al., 2013 · Open in CIViC	civic
Ivosidenib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5987 A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed mol… (full text at CIViC) PMID 27466707 · Brody et al., 2018 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Bevacizumab	CA Health Canada	—	Marketed in Canada as VEGZELMA (DIN 02534177) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 14, 2023	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as VEGZELMA (DIN 02534185) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 1, 2023	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as AYBINTIO (DIN 02522837) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 27, 2022	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as AYBINTIO (DIN 02522829) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 27, 2022	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as ABEVMY (DIN 02522179) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2022	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as ABEVMY (DIN 02522160) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2022	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as BAMBEVI (DIN 02520729) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 9, 2021	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as BAMBEVI (DIN 02520737) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 9, 2021	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as ZIRABEV (DIN 02489449) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 25, 2019	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as ZIRABEV (DIN 02489430) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 25, 2019	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as MVASI (DIN 02470748) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 1, 2019	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as MVASI (DIN 02470756) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 1, 2019	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as AVASTIN (DIN 02270994) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 2, 2005	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as BEVQOLVA (DIN 02567830) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as BEVQOLVA (DIN 02567865) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562502) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562499) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562472) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562480) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562464) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478358) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478315) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478307) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478323) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478331) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499312) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499304) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499282) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499339) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499347) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499320) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02481502) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02470705) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02470713) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02481499) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02470721) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02360810) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 2, 2011	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02360829) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 29, 2011	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02320193) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 4, 2009	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02293129) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2007	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02293145) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2007	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02293137) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2007	health-canada-dpd
Olaparib	CA Health Canada	—	Marketed in Canada as LYNPARZA (DIN 02475219) under ATC L01XK01 OLAPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 23, 2018	health-canada-dpd
Olaparib	CA Health Canada	—	Marketed in Canada as LYNPARZA (DIN 02475200) under ATC L01XK01 OLAPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 23, 2018	health-canada-dpd
Olaparib	CA Health Canada	—	Marketed in Canada as LYNPARZA (DIN 02454408) under ATC L01XK01 OLAPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 11, 2021	May 16, 2016	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02552906) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02552892) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02539284) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as AURO-SUNITINIB (DIN 02532190) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 18, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TEVA-SUNITINIB (DIN 02526220) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 11, 2023	health-canada-dpd

Associated cancers (13)

Drugs with predictive evidence (11)

Predictive evidence items (18)

Approvals mentioning the linked drugs (260)

Active trials (332)

Linked publications (25)